<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR7">
 <label>7.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Noh</surname>
    <given-names>SH</given-names>
   </name>
   <name>
    <surname>Park</surname>
    <given-names>SR</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>HK</given-names>
   </name>
   <name>
    <surname>Chung</surname>
    <given-names>HC</given-names>
   </name>
   <name>
    <surname>Chung</surname>
    <given-names>IJ</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>SW</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>HH</given-names>
   </name>
   <name>
    <surname>Choi</surname>
    <given-names>JH</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>HK</given-names>
   </name>
   <name>
    <surname>Yu</surname>
    <given-names>W</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial</article-title>
  <source>Lancet Oncol</source>
  <year>2014</year>
  <volume>15</volume>
  <issue>12</issue>
  <fpage>1389</fpage>
  <lpage>1396</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(14)70473-5</pub-id>
  <pub-id pub-id-type="pmid">25439693</pub-id>
 </element-citation>
</ref>
